Descripción:

NSABP PROTOCOL B-38Treatment Form for Group 2 - Doxorubicin, Cyclophosphamide Followed by Paclitaxel (DD AC - P) - Form T2 NCT00093795 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DD882133-10FD-25D3-E034-0003BA12F5E7

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DD882133-10FD-25D3-E034-0003BA12F5E7
Palabras clave:
  1. 18/12/14 18/12/14 - Martin Dugas
  2. 9/1/15 9/1/15 - Martin Dugas
  3. 16/6/15 16/6/15 -
Subido en:

16 de junio de 2015

DOI:
Para solicitar uno, por favor iniciar sesión.
Licencia :
Creative Commons BY-NC 3.0 Legacy
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

NSABP PROTOCOL B-38Treatment Form for Group 2 - Doxorubicin, Cyclophosphamide Followed by Paclitaxel (DD AC - P) - Form T2 NCT00093795

No Instruction available.

  1. StudyEvent: NSABP PROTOCOL B-38Treatment Form for Group 2 - Doxorubicin, Cyclophosphamide Followed by Paclitaxel (DD AC - P) - Form T2
    1. No Instruction available.
Assessment of Chemotherapy
Are data amended? (check box if yes, and circle amended items)
Agent Name (Agent Total Dose* mg/m^2)
Was this cycle delayed due to adverse event(s)? (Circle Y or N for Yes, No)
Reason Treatment Ended (or Never Started Select only one)

Similar models

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial